Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study-Reference-Cited by-同舟云学术

Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study

Published:2015-01 Issue:1 Volume:10 Page:28915
ISSN:1748-2631
Container-title:International Journal of Qualitative Studies on Health and Well-being
language:en
Short-container-title:International Journal of Qualitative Studies on Health and Well-being

Author:

Palareti Laura¹,Potì Silvia¹,Cassis Frederica²,Emiliani Francesca¹,Matino Davide³,Iorio Alfonso³

Affiliation:

1. Department of Education StudiesUniversity of Bologna, Bologna, Italy

2. Hemophilia CenterUniversity of São Paulo Faculty of Medicine Clinics Hospital, São Paulo, Brazil

3. Health Information Research UnitDepartment of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

Publisher

Informa UK Limited

Subject

Health Policy,Fundamentals and skills,Gerontology,Issues, ethics and legal aspects

Link

https://www.tandfonline.com/doi/pdf/10.3402/qhw.v10.28915

Reference11 articles.

1. Supporting adherence and improving quality of life in haemophilia care

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives;Seminars in Thrombosis and Hemostasis;2024-05-31

2. A Retrospective Observational Study of Quality of Life in a Northern Greece Population of People with Haemophilia;Life;2024-05-29

3. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy;Haemophilia;2024-03-10

4. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B;Expert Review of Hematology;2023-11-12

5. Imunodeficiência de imunoglobulinas IgG subclasse 3;Serviço Social e Saúde;2022-10-18